Sanofi’s rare disease drug finds yet another home
Over the past decade, the medicine Enjaymo has been passed around no less than five times by developers large and
October 5, 2024
Over the past decade, the medicine Enjaymo has been passed around no less than five times by developers large and
Dive Brief: Gene editing company Editas Medicines has sold off license fees and future payments it’s owed under an agreement
Dive Brief: Shortages affecting the availability of Eli Lilly’s top-selling diabetes and weight-loss drugs have now been resolved, the Food
The U.S. government is fine-tuning the rules for how it will negotiate drug prices within Medicare when the second round
Dive Brief: Eli Lilly on Wednesday announced plans to spend $4.5 billion on a new facility that will use advancements
Dive Brief: Gilead on Wednesday said it signed royalty-free licensing agreements with six generic drugmakers to produce and sell its
Today, a brief rundown of news from IGM Biosciences and Metsera, as well as updates from Gritstone Bio, UCB and
With rare exceptions, biotechnology and pharmaceutical companies validate their business plans through clinical trials, results from which are often presented
Boston-based Aktis Oncology has raised $175 million in fresh funding to advance its pipeline of radiopharmaceutical medicines for cancer. The
Dive Brief: Roche on Monday agreed to pay $850 million to acquire two experimental breast cancer drugs being developed by